ProShare Advisors
PHAT icon

ProShare Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

ProShare Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$114K Sell
10,246
-131
-1% -$1.66K ﹤0.01% 1685
2025
Q4 		$172K Buy
+10,377
New +$148K ﹤0.01% 1766
2025
Q3 		– Sell
-11,265
Closed -$108K – 2087
2025
Q2 		$108K Sell
11,265
-449
-4% -$2.48K ﹤0.01% 1866
2025
Q1 		$73.4K Sell
11,714
-2,575
-18% -$15.6K ﹤0.01% 1892
2024
Q4 		$116K Buy
14,289
+3,804
+36% +$47.1K ﹤0.01% 2043
2024
Q3 		$190K Buy
+10,485
New +$147K ﹤0.01% 1742

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return